Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836251 · ClinicalTrials.gov registry record
Effects of Antipsychotic Medications on Energy Intake and Expenditure
A clinical trial of Schizophrenia and Schizoaffective Disorder, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT00836251 is a study of Schizophrenia and Schizoaffective Disorder that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00836251, a study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Aim 1: To evaluate the effect of antipsychotic treatment group on Activity Energy Expenditure. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater decrease in AEE over time than subjects treated with ziprasidone, due at least in part to sedating effects of olanzapine. Aim 2: To evaluate the effect of antipsychotic treatment group on Energy Intake. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater increase in EI over time than subjects treated with ziprasidone, based on higher histamine type 1 (H1) receptor affinity of olanzapine and the relationship between H1 affinity and hunger and/or satiety.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT H218O and 2H2O, administered as a mixed cocktail
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836251
The ClinicalTrials.gov registry entry for NCT00836251 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which H218O and 2H2O, administered as a mixed cocktail is the first listed.
NCT00836251 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00836251 about?
NCT00836251 is a clinical study titled "Effects of Antipsychotic Medications on Energy Intake and Expenditure". Aim 1: To evaluate the effect of antipsychotic treatment group on Activity Energy Expenditure. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater decrease in AEE over time than subjects treated with ziprasidone, due at least in part to sedating effects of olanz...
What is the current status of trial NCT00836251?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2006-04. Estimated completion is 2008-06.
What conditions does trial NCT00836251 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Weight Gain.
What interventions are being tested in trial NCT00836251?
The interventions under investigation include: H218O and 2H2O, administered as a mixed cocktail (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00836251?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00836251 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.